In clinical setting, a small cohort study with limited cases also showed that EGFR-TKIs plus bisphosphonates could significantly prolong PFS and OS in patients with EGFR mutant NSCLC and BM than those received EGFR-TKIs alone as the first-line therapy (PFS: 15.0 vs 7.3 months, P = 0.03; OS: 25.2 vs 10.4 months, P = 0.0015)19. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.